Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
2005-04-15
2011-12-06
Hui, San-Ming (Department: 1628)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C514S182000
Reexamination Certificate
active
08071577
ABSTRACT:
The multiphase preparation having higher contraceptive safety and reduced side effects is based on a combination of a natural oestrogen with dienogest or drospirenone. The multiphase preparation is characterized by a first phase consisting of 2 daily dose units of 3 mg of oestradiol valerate, a second phase consisting of 2 groups of daily dose units, wherein a first group is formed by 5 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least two or three times an ovulation-inhibitory dose of dienogest or drospirenone and a second group is formed by 17 daily dose units each containing a combination of 2 mg of oestradiol valerate and at least three or four times the ovulation-inhibitory dose of dienogest or drospirenone, a third phase consisting of 2 daily dose units of 1 mg of oestradiol valerate, and a further phase consisting of 2 daily dose units of pharmaceutically acceptable placebo.
REFERENCES:
patent: 3639600 (1972-02-01), Hendrix
patent: 3795734 (1974-03-01), Rochefort
patent: 3957982 (1976-05-01), Lachnit-Fixson et al.
patent: 4066757 (1978-01-01), Pasquale
patent: 4272270 (1981-06-01), Higgins et al.
patent: 4378356 (1983-03-01), DeJager
patent: 4390531 (1983-06-01), Edgren
patent: 4530839 (1985-07-01), Pasquale
patent: 4544554 (1985-10-01), Pasquale
patent: 4616006 (1986-10-01), Pasquale
patent: 4621079 (1986-11-01), Lachnit-Fixson et al.
patent: 4628051 (1986-12-01), Pasquale
patent: 4921843 (1990-05-01), Pasquale
patent: 5280023 (1994-01-01), Ehrlich et al.
patent: 5583129 (1996-12-01), Spona et al.
patent: 5633242 (1997-05-01), Oettel et al.
patent: 6027749 (2000-02-01), Schmidt-Gollwitzer et al.
patent: 6133251 (2000-10-01), Dittgen et al.
patent: 6312722 (2001-11-01), Schmidt-Gollwitzer et al.
patent: 6670350 (2003-12-01), Oettel et al.
patent: 6782282 (2004-08-01), Bielefeldt et al.
patent: 6884793 (2005-04-01), Dittgen et al.
patent: 6987101 (2006-01-01), Nashed
patent: 2002/0107229 (2002-08-01), Dittgen et al.
patent: 2004/0266745 (2004-12-01), Schwanitz et al.
patent: 2005/0032756 (2005-02-01), Dittgen et al.
patent: 2005/0282790 (2005-12-01), Nashed
patent: 2006/0135496 (2006-06-01), DiLiberti et al.
patent: 2007/0111977 (2007-05-01), Zeun et al.
patent: 2007/0259840 (2007-11-01), Endrikat et al.
patent: 2008/0125401 (2008-05-01), Zeun et al.
patent: 823 689 (1975-06-01), None
patent: 1 090 255 (1980-11-01), None
patent: 2140011 (1994-01-01), None
patent: 2 431 704 (1976-01-01), None
patent: 2 645 307 (1978-04-01), None
patent: 3 341 638 (1984-05-01), None
patent: 3 347 125 (1985-07-01), None
patent: 41 04 385 (1992-08-01), None
patent: 42 24 534 (1994-01-01), None
patent: 43 08 406 (1994-06-01), None
patent: 4 339 934 (1994-11-01), None
patent: 43 13 926 (1994-11-01), None
patent: 4 344 462 (1995-06-01), None
patent: 4 429 374 (1996-02-01), None
patent: 44 29 374 (1996-02-01), None
patent: 26229 (1981-04-01), None
patent: 0 226 679 (1987-07-01), None
patent: 253607 (1988-01-01), None
patent: 0 378 373 (1990-07-01), None
patent: 0 491 415 (1992-06-01), None
patent: 0 696 454 (1996-02-01), None
patent: 0 770 388 (1997-05-01), None
patent: 0 770 388 (1997-05-01), None
patent: 0 911 029 (2002-04-01), None
patent: 0 835 114 (2003-05-01), None
patent: 1 462 106 (2004-09-01), None
patent: 1 787 649 (2007-05-01), None
patent: 6 911 920 (1970-02-01), None
patent: WO-92 13539 (1992-08-01), None
patent: WO 95/07081 (1995-03-01), None
patent: WO-98 04265 (1998-02-01), None
patent: WO98/04268 (1998-02-01), None
patent: WO 98/04268 (1998-02-01), None
patent: WO-98 04269 (1998-02-01), None
patent: WO 98/27929 (1998-07-01), None
patent: WO-02 22110 (2002-03-01), None
patent: 2004/112797 (2004-12-01), None
patent: WO 2004/112797 (2004-12-01), None
patent: WO 2005/102247 (2005-11-01), None
patent: WO 2007/002862 (2007-01-01), None
patent: 8 509 892 (1986-07-01), None
Awward, J. T. et al., “Abnormal uterine bleeding in the perimenopause,” Int. J. Fertil., 1993, vol. 38, pp. 261-269.
Speroff et al., “Clinical Gynecologic Endocrinology and infertility,” Lippincott, Williams, and Wilkins: Sixth Edition, 1999, pp. 575-593.
Fraser, I. S. et al., “Treatment of Ovulatory and Anovulatory Dysfunctional Uterine Bleeding With Oral Progestogens,” Aust. NZ. J. Obetet. Gynaecol., 1990, vol. 30, No. 4, pp. 353-356.
Hickey, M et al., “Progestogens Versus oestrogens and progestogens for irregular uterine bleeding associated with anovulation,” The Cochrane Database of Systematic Review, 2000, vol. 1, pp. 1-9.
Steiner, R. et al., “Abnormal Menstrual Bleeding,” Schweiz Rundsch. Med. Prax., 2002, vol. 91, pp. 1967-1974.
Opposition filed by Sandoz International GmbH against EP1787649 on Nov. 26, 2009.
English Translation of Opposition filed by Sandoz International GmbH against EP1787649 on Nov. 26, 2009.
Goretzlehner, G. et al., “Zur Nomenklatur der Zyklusstorungen,” Frauenarzt, 2005, vol. 46, No. 1, pp. 34-37.
Tapanainen, J. S., “Medical management of menstral disorders,” International Congress Series, 2004, vol. 1266, pp. 63-68.
Golbs, S. et al., “Clinical Findings with the Oral Contraceptive Combination Ethinylestradiol/ Dienogest in Poland,” Methods Find Exp Clin Pharmacol, 2002, vol. 24, No. 9, pp. 585-592.
Golbs, S. et al., “Clinical Findings with the Oral Contraceptive Combination Ethinylestradiol/ Dienogest in the Czech Republic,” Methods Find Exp. Clin. Pharmacol., vol. 24, No. 10, pp. 689-696.
Mueck, A. O. et al., “Effect on biochemical vasoactive markers during postmenopausal hormone response replacement therapy: estradiol versus estradiol/dienogest,” Maturitas, 2001, vol. 38, pp. 305-313.
Kuhl, H. et al., “Aktuelle Entwicklungen in der hormonalen Kontrazeption,” Gynakologe, 1992, vol. 25, pp. 231-240.
Watson Pharma, Inc., “About Oral Contraceptives (OCs),” Retrieved from http://www.oralcontraceptives.com/about—benefits.asp on Apr. 5, 2010.
Davis, A. J. et al., “Advances in Contraception,” Obstet. Gynecol. Clin. North. Am., Sep. 2000, vol. 27, No. 3, pp. 597-610.
Conrad, J. et al., “Natural Estrogens for Oral Contraception,” The Lancet, Sep. 1, 1979, pp. 471.
Moller, Svend E., “Deaths of Infants After Triple Vaccine,” The Lancet, Sep. 1, 1979, pp. 472.
Carlborg, Lars, “Comparison of Contraception Acceptability of Levonorgestrel and Ethinyl Oestradiol Administered in one Three-Phasic (Trionetta) and one Monophasic (Neovletta) Version” Contraception, May 1983, vol. 27, No. 5, pp. 439-452.
Guenferich, Peter F., “Oxidation of 17 alpha-Ethynylestradiol by Human Liver Cytochrome p-450,” Molecular Pharmacology, vol. 33, pp. 500-508, 1988.
Bocker, R. “In vitro interaction of contraception steroids with human liver cytochrome P-450 enzymes,” Department of Toxicology and Pharmacology, University of Erlangen-Nurnberg, pp. 141-148, 1991.
Zhu, Bao Ting et al., “The Carcinogenic Activitiy of Ethinyl Estrogens is Determined by Both Their Hormonal Characteristics and Their Conversion to Catechol Metabolites,” Endocrinology, vol. 132, No. 2, 1993, pp. 577-583.
Hirvonen, E. et al., “Oral Contraceptives containing natural estradiol for premenopausal women,” Maturitas, 1995, vol. 21, pp. 27-32.
Wenzl, Rene et al., “Ovulation inhibition with a combined oral contraceptive containing 1 mg micronized 17 beta-estradiol,” Fertility and Sterility, Oct. 1993, vol. 60, No. 4, pp. 616-619.
Elstein, Max et al., “Studies on Low-dose oral contraceptives: Cervial mucus and plasma hormone changes in relation to circulating d-norgestrel and 17 alpha-ethynyl estradiol concentrations,” Fertility and Sterility, Aug. 1976, vol. 27, No. 8, pp. 892-899.
Aktories, K. et al., “Die Beeinflussung des Ovarialzyklus durch verschiedene Typen hormonaler Kontrazeptiva,” Geburtsch. U. Frauenheilk, 1976, vol. 36, pp. 318-326.
World Health Organization Task Force on Oral Contracep
Duesterberg Bernd
Endrikat Jan
Bayer Pharma Aktiengesellschaft
Hui San-Ming
Millen White Zelano & Branigan P.C.
LandOfFree
Multi-phase contraceptive preparation based on a natural... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Multi-phase contraceptive preparation based on a natural..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Multi-phase contraceptive preparation based on a natural... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4313333